Published in J Biol Chem on January 15, 2004
The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J (2004) 3.92
Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A (2005) 3.16
FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res (2011) 1.80
Upregulation of MircoRNA-370 induces proliferation in human prostate cancer cells by downregulating the transcription factor FOXO1. PLoS One (2012) 1.30
FSH and FOXO1 regulate genes in the sterol/steroid and lipid biosynthetic pathways in granulosa cells. Mol Endocrinol (2009) 1.27
Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene (2005) 1.12
Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. Hum Pathol (2007) 1.06
Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer. Am J Cancer Res (2011) 1.04
Unraveling the role of FoxOs in bone--insights from mouse models. Bone (2011) 0.96
FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants. Prostate (2013) 0.94
Inhibition of the progesterone nuclear receptor during the bone linear growth phase increases peak bone mass in female mice. PLoS One (2010) 0.92
The use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression. BMC Genomics (2006) 0.90
Activation of FOXO1 is critical for the anticancer effect of methylseleninic acid in prostate cancer cells. Prostate (2010) 0.86
Inhibition of cyclin-dependent kinase phosphorylation of FOXO1 and prostate cancer cell growth by a peptide derived from FOXO1. Neoplasia (2011) 0.85
Evidence for an association between increased oxidative stress and derangement of FOXO1 signaling in tumorigenesis of a cellular angiofibroma with monoallelic 13q14: a case report. Int J Clin Exp Pathol (2014) 0.84
Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures. J Cancer Sci Ther (2012) 0.81
The function of FOXO1 in the late phases of the cell cycle is suppressed by PLK1-mediated phosphorylation. Cell Cycle (2014) 0.79
Decreased expression of FOXF2 as new predictor of poor prognosis in stage I non-small cell lung cancer. Oncotarget (2016) 0.76
GIT2 Acts as a Systems-Level Coordinator of Neurometabolic Activity and Pathophysiological Aging. Front Endocrinol (Lausanne) (2016) 0.75
Testosterone supplementation improves glucose homeostasis despite increasing hepatic insulin resistance in male mouse model of type 2 diabetes mellitus. Nutr Diabetes (2016) 0.75
Molecular Targeted Therapies Using Botanicals for Prostate Cancer Chemoprevention. Transl Med (Sunnyvale) (2012) 0.75
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
Dynamic FoxO transcription factors. J Cell Sci (2007) 6.30
Mechanisms of androgen-refractory prostate cancer. N Engl J Med (2004) 4.49
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev (2007) 3.54
CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science (2006) 3.41
Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res (2002) 3.26
Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A (2005) 3.16
Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol (2011) 2.99
Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-Ms/MS using protein cleavage and isotope dilution mass spectrometry. J Proteome Res (2004) 2.85
Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol (2008) 2.68
Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol (2007) 2.53
Alternatively spliced androgen receptor variants. Endocr Relat Cancer (2011) 2.41
Utilizing artificial neural networks in MATLAB to achieve parts-per-billion mass measurement accuracy with a fourier transform ion cyclotron resonance mass spectrometer. J Am Soc Mass Spectrom (2009) 2.02
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet (2003) 1.96
Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 1.90
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A (2005) 1.85
Molecular regulation of androgen action in prostate cancer. J Cell Biochem (2006) 1.81
Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest (2009) 1.64
Chromatin assembly factor 1 interacts with histone H3 methylated at lysine 79 in the processes of epigenetic silencing and DNA repair. Biochemistry (2006) 1.61
Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. J Proteome Res (2007) 1.60
Performance characteristics of a new hybrid quadrupole time-of-flight tandem mass spectrometer (TripleTOF 5600). Anal Chem (2011) 1.59
Generation and detection of multiply-charged peptides and proteins by matrix-assisted laser desorption electrospray ionization (MALDESI) Fourier transform ion cyclotron resonance mass spectrometry. J Am Soc Mass Spectrom (2006) 1.55
Mass spectrometry-based biomarker discovery: toward a global proteome index of individuality. Annu Rev Anal Chem (Palo Alto Calif) (2009) 1.54
Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochim Biophys Acta (2011) 1.52
MSiReader: an open-source interface to view and analyze high resolving power MS imaging files on Matlab platform. J Am Soc Mass Spectrom (2013) 1.51
p300 in prostate cancer proliferation and progression. Cancer Res (2003) 1.50
Androgen regulation of gene expression. Adv Cancer Res (2010) 1.47
Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol (2007) 1.44
Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J Biol Chem (2006) 1.43
Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol (2011) 1.43
New developments in the medical management of prostate cancer. Mayo Clin Proc (2010) 1.41
Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res (2009) 1.39
FOXO factors: a matter of life and death. Future Oncol (2006) 1.35
Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells. Cancer Res (2007) 1.34
A method for calculating 16O/18O peptide ion ratios for the relative quantification of proteomes. J Am Soc Mass Spectrom (2004) 1.34
Detection of genetic variants of transthyretin by liquid chromatography-dual electrospray ionization fourier-transform ion-cyclotron-resonance mass spectrometry. Clin Chem (2004) 1.32
Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res (2012) 1.30
p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res (2002) 1.29
A method for automatically interpreting mass spectra of 18O-labeled isotopic clusters. Mol Cell Proteomics (2006) 1.27
Accessible proteomics space and its implications for peak capacity for zero-, one- and two-dimensional separations coupled with FT-ICR and TOF mass spectrometry. J Mass Spectrom (2006) 1.25
FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth. J Clin Invest (2010) 1.25
Coupling of a vented column with splitless nanoRPLC-ESI-MS for the improved separation and detection of brain natriuretic peptide-32 and its proteolytic peptides. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.23
Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther (2009) 1.22
Dual electrospray ionization source for confident generation of accurate mass tags using liquid chromatography Fourier transform ion cyclotron resonance mass spectrometry. Anal Chem (2003) 1.22
Regulation of androgen receptor signaling in prostate cancer. Expert Rev Anticancer Ther (2005) 1.21
Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer. Cancer Res (2007) 1.19
Development of a robust and high throughput method for profiling N-linked glycans derived from plasma glycoproteins by NanoLC-FTICR mass spectrometry. J Proteome Res (2009) 1.19
Coordination-driven self-assembly of metallodendrimers possessing well-defined and controllable cavities as cores. J Am Chem Soc (2007) 1.18
The role of androgens and the androgen receptor in prostate cancer. Cancer Lett (2002) 1.18
Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients. Anal Chem (2009) 1.17
Identification of transthyretin variants by sequential proteomic and genomic analysis. Clin Chem (2004) 1.17
RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Mol Endocrinol (2012) 1.16
Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci (2013) 1.16
Infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) imaging source coupled to a FT-ICR mass spectrometer. J Am Soc Mass Spectrom (2012) 1.15
Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1. Cancer Res (2009) 1.15
Androgen modulation of coregulator expression in prostate cancer cells. Mol Endocrinol (2009) 1.14
Gentle protein ionization assisted by high-velocity gas flow. Anal Chem (2005) 1.13
PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin Cancer Res (2006) 1.13
Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res (2007) 1.12
p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res (2005) 1.10
Molecular architecture via coordination: self-assembly of nanoscale hexagonal metallodendrimers with designed building blocks. J Am Chem Soc (2006) 1.10
Construction of a versatile high precision ambient ionization source for direct analysis and imaging. J Am Soc Mass Spectrom (2008) 1.10
A new family of multiferrocene complexes with enhanced control of structure and stoichiometry via coordination-driven self-assembly and their electrochemistry. J Am Chem Soc (2008) 1.09
Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride. Prostate (2007) 1.09
Advantages of Thermococcus kodakaraenis (KOD) DNA Polymerase for PCR-mass spectrometry based analyses. J Am Soc Mass Spectrom (2003) 1.08
TGF-betal/Smad signaling in prostate cancer. Curr Drug Targets (2003) 1.08
The role of the androgen receptor in prostate cancer. Crit Rev Eukaryot Gene Expr (2002) 1.08
Discovery of ovarian cancer biomarkers in serum using NanoLC electrospray ionization TOF and FT-ICR mass spectrometry. Dis Markers (2004) 1.08
A highly efficient approach to the self-assembly of hexagonal cavity-cored tris[2]pseudorotaxanes from several components via multiple noncovalent interactions. J Am Chem Soc (2007) 1.08
Stable-isotope labeled hydrophobic hydrazide reagents for the relative quantification of N-linked glycans by electrospray ionization mass spectrometry. Anal Chem (2011) 1.07
Direct comparison of stable isotope labeling by amino acids in cell culture and spectral counting for quantitative proteomics. Anal Chem (2010) 1.07
Targeting 5α-reductase for prostate cancer prevention and treatment. Nat Rev Urol (2011) 1.06
Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer (2008) 1.06
Identification of subunit-subunit interactions in bacteriophage P22 procapsids by chemical cross-linking and mass spectrometry. J Proteome Res (2006) 1.05
Membrane protein complexes catalyze both 4- and 3-hydroxylation of cinnamic acid derivatives in monolignol biosynthesis. Proc Natl Acad Sci U S A (2011) 1.05
Intact and top-down characterization of biomolecules and direct analysis using infrared matrix-assisted laser desorption electrospray ionization coupled to FT-ICR mass spectrometry. J Am Soc Mass Spectrom (2008) 1.05
Improving proteome coverage on a LTQ-Orbitrap using design of experiments. J Am Soc Mass Spectrom (2011) 1.04
p300 modulates nuclear morphology in prostate cancer. Cancer Res (2005) 1.04
IR-MALDESI mass spectrometry imaging of biological tissue sections using ice as a matrix. J Am Soc Mass Spectrom (2014) 1.04
Evaluation of normalization methods on GeLC-MS/MS label-free spectral counting data to correct for variation during proteomic workflows. J Am Soc Mass Spectrom (2011) 1.03
Coordination-driven self-assembly of cavity-cored multiple crown ether derivatives and poly[2]pseudorotaxanes. J Am Chem Soc (2008) 1.03
Oxidative stress and DNA methylation in prostate cancer. Obstet Gynecol Int (2010) 1.03
Direct characterization of intact polypeptides by matrix-assisted laser desorption electrospray ionization quadrupole Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun Mass Spectrom (2007) 1.02
Poly specific trans-acyltransferase machinery revealed via engineered acyl-CoA synthetases. ACS Chem Biol (2012) 1.02
Quantitative top-down proteomics of SILAC labeled human embryonic stem cells. J Am Soc Mass Spectrom (2010) 1.01
Dual electrospray ion source for electron-transfer dissociation on a hybrid linear ion trap-orbitrap mass spectrometer. Anal Chem (2007) 1.01
Complete proteomic-based enzyme reaction and inhibition kinetics reveal how monolignol biosynthetic enzyme families affect metabolic flux and lignin in Populus trichocarpa. Plant Cell (2014) 1.01
Accurate mass precursor ion data and tandem mass spectrometry identify a class I human leukocyte antigen A*0201-presented peptide originating from vaccinia virus. J Am Soc Mass Spectrom (2005) 1.00
Analytical performance of a venturi device integrated into an electrospray ionization fourier transform ion cyclotron resonance mass spectrometer for analysis of nucleic acids. Anal Chem (2004) 1.00
Absolute quantification of C-reactive protein in human plasma derived from patients with epithelial ovarian cancer utilizing protein cleavage isotope dilution mass spectrometry. J Proteome Res (2009) 0.99
Direct high-resolution peptide and protein analysis by desorption electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun Mass Spectrom (2006) 0.99
Comparison of stable-isotope labeling with amino acids in cell culture and spectral counting for relative quantification of protein expression. Rapid Commun Mass Spectrom (2011) 0.99
Interplay of permanent charge and hydrophobicity in the electrospray ionization of glycans. Anal Chem (2010) 0.99
Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. Mol Cancer Ther (2008) 0.99
Development and characterization of an ionization technique for analysis of biological macromolecules: liquid matrix-assisted laser desorption electrospray ionization. Anal Chem (2008) 0.97